sur ADVICENNE (EPA:ADVIC)
Advicenne Reports Solid Growth and Future Plans for 2025
In 2024, Advicenne, a specialty pharmaceutical company, reported a 9.4% increase in product sales, totaling €4.9 million. Sibnayal® notably surged over 130% in Europe, reaching €6.0 million. Advicenne's cash position stood at €3.2 million by year-end, with a financing horizon until June 2025.
Significant progress was made for ADV7103 in the U.S. for two conditions, expecting an NDA filing in dRTA by Q3 2025. Advicenne aims to extend its cash beyond mid-2025 through potential partnerships and discussions with lenders.
Operating expenses decreased by over 15% despite higher costs, with net losses improving from €7.53 million in 2023 to €6.46 million in 2024. The agreement with Primex Pharmaceuticals boosted cash flow and reduced operating cash consumption significantly.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ADVICENNE